Requests from stakeholders have led the FDA to extend the comment period to Feb. 5 on a proposed rule on good manufacturing practices (GMPs) for combination products. Under the proposed rule, companies could develop written procedures for a streamlined system to show compliance with GMPs for drugs or biologics and quality system requirements for devices.
Washington Drug Letter